KR20230024347A - 급성 심방 세동의 치료를 위한 설카르딘 투여 - Google Patents

급성 심방 세동의 치료를 위한 설카르딘 투여 Download PDF

Info

Publication number
KR20230024347A
KR20230024347A KR1020237000723A KR20237000723A KR20230024347A KR 20230024347 A KR20230024347 A KR 20230024347A KR 1020237000723 A KR1020237000723 A KR 1020237000723A KR 20237000723 A KR20237000723 A KR 20237000723A KR 20230024347 A KR20230024347 A KR 20230024347A
Authority
KR
South Korea
Prior art keywords
sulcardine
administration
pharmaceutically acceptable
acceptable salt
tmax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237000723A
Other languages
English (en)
Korean (ko)
Inventor
게리 엘리오트
미릴 길링스
로버트 구데노우
제이 메이슨
발데마르 라지제브스키
수잔 로마노
Original Assignee
후야바이오 인터내셔널, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후야바이오 인터내셔널, 엘엘씨 filed Critical 후야바이오 인터내셔널, 엘엘씨
Publication of KR20230024347A publication Critical patent/KR20230024347A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237000723A 2020-06-12 2021-06-11 급성 심방 세동의 치료를 위한 설카르딘 투여 Pending KR20230024347A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
US63/038,664 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
KR20230024347A true KR20230024347A (ko) 2023-02-20

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000723A Pending KR20230024347A (ko) 2020-06-12 2021-06-11 급성 심방 세동의 치료를 위한 설카르딘 투여

Country Status (14)

Country Link
US (2) US11813245B2 (https=)
EP (1) EP4164633A4 (https=)
JP (1) JP2023529196A (https=)
KR (1) KR20230024347A (https=)
CN (1) CN116723836A (https=)
AU (1) AU2021288056A1 (https=)
BR (1) BR112022025216A2 (https=)
CA (1) CA3182015A1 (https=)
CL (1) CL2022003501A1 (https=)
CO (1) CO2023000194A2 (https=)
IL (1) IL298907A (https=)
MX (1) MX2022015834A (https=)
PH (1) PH12022553396A1 (https=)
WO (1) WO2021252959A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
EP2501381B1 (en) * 2009-11-17 2017-07-26 Huya Bioscience International LLC Treatment of atrial fibrillation
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) * 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) * 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Also Published As

Publication number Publication date
CO2023000194A2 (es) 2023-03-27
PH12022553396A1 (en) 2024-04-22
JP2023529196A (ja) 2023-07-07
MX2022015834A (es) 2023-04-04
CL2022003501A1 (es) 2023-06-09
WO2021252959A1 (en) 2021-12-16
US20240058304A1 (en) 2024-02-22
IL298907A (en) 2023-02-01
CA3182015A1 (en) 2021-12-16
EP4164633A4 (en) 2024-07-31
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
US11813245B2 (en) 2023-11-14
BR112022025216A2 (pt) 2023-04-04
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09
CN116723836A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
US12357611B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
KR20160108611A (ko) 심방세동의 치료 방법
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
JP2011517694A (ja) ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
US20260041665A1 (en) J-Tp Protection
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
EP3836918B1 (en) Task-1 inhibitors for use in the treatment of atrial arrhythmias
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
EP1868598A2 (en) A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
WO2011141888A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240610

Comment text: Request for Examination of Application